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Previewshomeostasis and integrity, oncogene
activation, or inflammatory insults result
in the induction of chemokines and cyto-
kines that shape the local microenviron-
ment. Recruited immune cells and CAF,
as well as altered epithelial and neoplastic
cells, continue to produce cytokines
(such as IL-6) that activate oncogenic
transcription factors (i.e., STAT3), further
sustaining tumor-associated inflamma-
tion. This paradigm applies not only to
pancreatic or esophageal cancers, but
also to the majority of solid malignancies.
This implies that drugs that disrupt tumor-
associated inflammation, either by target-
ing STAT3 activating kinases (e.g., JAK2)
or key proinflammatory cytokines, such
as IL-6, should have significant thera-
peutic and preventive effects in a variety
of cancers, regardless of their origin.ACKNOWLEDGMENTS
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In this issue of Cancer Cell, Mazzieri, Pucci, and colleagues describe the marked effects of inhibiting the
proangiogenic cytokine, Angiopoietin-2, on tumor angiogenesis and progression in spontaneous tumor
models, as well as the proangiogenic functions of TIE2-expressing macrophages.A number of antiangiogenic agents have
now been developed to inhibit vascular
endothelial growth factor (VEGF) signaling
pathway in tumors. Like the majority
of existing anticancer therapies, their
clinical efficacy is limited by the transient
nature of their inhibitory effects on
advanced tumors. In severalmouse tumor
models, VEGF inhibition results in marked
suppression of tumor angiogenesis, which
often leads to reduced tumor growth and
even tumor shrinkage. However, tumors
usually revascularize and grow back
upon prolonged treatment. This escape
from VEGF blockade is thought to be
due to various mechanisms, including
the upregulation of alternative proangio-genic growth factors, the enhanced inva-
sive/metastatic activity of tumor cells
(to locate an alternative blood supply),
and the increased recruitment of proan-
giogenic bone marrow-derived cells to
the tumor site, where they promote tumor
revascularization andgrowth (Bergers and
Hanahan, 2008).
A major finding in the latter area has
been that certain inflammatory cell types
convey tumor resistance to antiangio-
genic therapies. For example, Shojaei
et al. (2007) showed, in murine tumor
models, that tumor-infiltrating CD11b+
Gr1+myeloid cells can induce tumor resis-
tance to VEGF therapy via their release of
Bv8 (prokineticin-1), a proangiogeniccytokine stimulated by their exposure to
tumor cell-derived granulocyte colony-
stimulating factor (G-CSF). In this way,
certain mouse tumors treated with anti-
VEGF drugs are able to circumvent their
dependency on VEGF and render them-
selves resistant to anti-VEGF therapy.
Proangiogenic myeloid cells are also
thought to be recruited in response to the
elevated release of such chemoattractants
as CXCL12 (stromal cell-derived factor-1,
SDF1) by hypoxic areas of therapy-
damaged tumors (Kioi et al., 2010). Among
the most essential of these are a high-
ly proangiogenic subset of monocytes/
macrophages that express the angio-
poietin receptor, TIE2, and so are termedl 19, April 12, 2011 ª2011 Elsevier Inc. 431
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Figure 1. Targeting ANG2 or TIE2 on TEMs Has Pronounced Effects on the Tumor Vasculature
(Left panel) TEMs upregulate TIE2 upon entry to tumors and locate around angiogenic blood vessels. At these sites, they are exposed to ANG2 (released by the
vessels as well as possibly cells in hypoxic areas).
(Top right panel) Treatment with ANG2 antibody causes vessel regression, increased hypoxia, blocks the increase in TIE2 on tumor TEMs, and causes TEMs to
locate to sites distant from remnant blood vessels. This phenotype is associated with decreased metastasis to distant sites.
(Bottom right panel) Conditional knockdown of TIE2 in TEMs results in inhibition of tumor angiogenesis and again blocks TEM association with tumor vessels.
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(TEMs). These cells preferentially infiltrate
tumorswhere they upregulate their expres-
sion of TIE2, express anaggressive, tumor-
promoting phenotype and are essential for
tumor angiogenesis and progression
(De Palma and Naldini, 2009). Although
TEMs have yet to be implicated in tumor
resistance to anti-VEGF therapy, they
appear to be involved in tumor recurrence
after local irradiation (Kioi et al., 2010).
An interesting picture has emerged
recently of one way in which the tumor
microenvironment stimulates the tumor-
promoting functions of TEMs. Angiopoie-
tin-2 (ANG2), a cytokine upregulated in
tumors mainly by endothelial cells and
some malignant cells, stimulates tumor
angiogenesis in concert with other proan-
giogenic factors, namely VEGF (Augustin
et al., 2009). However, tumor-derived
ANG2 also stimulates the proangiogenic
functionsofTEMs (Coffelt etal., 2010), sug-
gesting thatnew therapeutic agents target-
ing theANG2–TIE2axismaynot only inhibit432 Cancer Cell 19, April 12, 2011 ª2011 Elstumor angiogenesis directly (by targeting
autocrine signaling on activated endothe-
lial cells) but also indirectly by inhibiting
TEMs. Furthermore, ANG2 is upregulated
by tumor hypoxia—a known consequence
of anticancer therapies—so it may further
enhance the tumor-promoting functions
of TEMs in treated tumors.
The study reported by Mazzieri et al.
(2011), in the current issue of Cancer Cell,
employed both a monoclonal antibody to
ANG2 (clone 3.19.3) and a novel condi-
tional lentiviral system for specifically
knocking down TIE2 in TEMs to demon-
strate the essential role of the ANG2/TIE2
axis in drivingTEM-mediated tumor angio-
genesis in various tumor models. ANG2
blockade induced vascular regression
and durable growth inhibition, irrespective
of whether it was administered to early or
late-stage spontaneous tumors. Impor-
tantly, no signs of tumor resistance were
evident in their tumor models, including
a spontaneous islet tumor model known
to develop resistance to anti-VEGF/evier Inc.VEGFR therapy (RIP1-Tag2) (Bergers and
Hanahan, 2008). At first glance, these find-
ings appear to be at variance with the fact
that tumor xenografts grown in ANG2-
deficient mice showed no sign of reduced
tumor angiogenesis and progression
(Nasarre et al., 2009). However, they
accord well with other recent studies
demonstrating the antitumor efficacy of
specific ANG2 inhibitors in mouse tumor
models (Huang et al., 2010). An equally
fascinating finding by Mazzieri et al.
(2011) is that theANG2blockade also sup-
pressed the metastatic spread of sponta-
neous mammary (MMTV-PyMT) tumors.
Further studies are now warranted to
investigate the ANG2-driven mechanisms
promoting metastasis in this and possibly
other tumor models.
Taken together, the above findings
highlight the potential therapeutic value
of specific ANG2 inhibitors, someofwhich
are currently being tested in clinical trials.
However, the degree of inhibition of tumor
growth elicited by AMG386, a peptide-Fc
Cancer Cell
Previewsfusion protein that blocks both ANG2 and
its sister molecule ANG1 (another TIE2
ligand, which has the opposite effects to
ANG2 on endothelial cells), appears to
be model-dependent (Coxon et al.,
2010). Both ANG1 and ANG2 were tar-
geted by AMG386 because ANG1-
specific antagonism was seen to increase
the inhibitory effects of ANG2-specific
antagonism on tumor growth (suggesting
that ANG1 and ANG2 may have coopera-
tive effects on tumor growth in some
models). Although specific ANG2 inhibi-
tors show efficacy in a wide array of tumor
models (Huang et al., 2010; Mazzieri et al.,
2011), it remains to be seen whether they
are also effective in a broad spectrum of
human tumor types.
The paper by Mazzieri et al. (2011) also
generated a number of unique insights
into the regulation of TEMs by ANG2 in
tumors (Figure 1). First, they showed
that the ANG2 blockade resulted in
increased TEM recruitment to tumors
(possibly via a hypoxia/CXCL12-driven
pathway) but prevented their upregulation
of TIE2 upon entry to the tumor site.
This suggests that ANG2 regulates TIE2
expression in TEMs, although whether
this operates via a direct effect on these
cells or indirectly via endothelial cells
has yet to be ascertained. Intriguingly,
disruption of the ANG2-TEM axis using
either their ANG2 antibody or the selec-
tive knockdown of TIE2 in TEMs impeded
TEM association with nascent tumor
blood vessels and disabled the proangio-
genic activity of TEMs. Although notdirectly addressed in their paper, the
authors propose a causal link between
the latter two events. Finally, they show
that TIE2 knockdown in TEMs led to
reduced tumor angiogenesis and vas-
cular perfusion but not the vessel regres-
sion and tumor growth inhibition seen
with the anti-ANG2 antibody. They specu-
late that this could be due to the
nonexhaustive knockdown of Tie2 in
TEMs. However, an alternative interpreta-
tion is that the growth-promoting effects
of ANG2 on tumors may not be mediated
by TEMs. Future studies will clarify and
extend these aspects of the study.
The full efficacy of anti-VEGF and other
antiangiogenic therapies is unlikely to be
realized until the mechanisms underlying
tumor resistance are fully understood
and then selectively inhibited. The results
described by Mazzieri et al. (2011) are
encouraging and suggest that targeting
the ANG2-TIE2 axis may represent
a promising antiangiogenic treatment
that inhibits not only key events in tumor
angiogenesis and metastasis, but also
the insidious myeloid cells recruited by
tumors to kick-start their recovery.
However, it should be remembered that,
to date, evidence for murine and human
tumors employing similar reparative
mechanisms after antiangiogenic therapy
remains scant. Phase II clinical studies
have recently shown that AMG386
improves progression-free survival in
ovarian cancer patients (Huang et al.,
2010), but we will have to wait to see
whether any of the selective ANG2 inhibi-Cancer Celtors currently in clinical trials have the
marked antitumor effects predicted by
the current study—either alone or in
combination with cytotoxic or other anti-
angiogenic agents.REFERENCES
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